Skip to content

Mastering Prostate Cancer Staging: Your Interactive Guide to Understanding & Navigating the Grading Systems

Spread the love

Last Updated on April 14, 2024 by Max


Welcome to “Mastering Prostate Cancer Staging” – an interactive and in-depth guide designed to demystify the complexities of prostate cancer staging and grading systems. Whether you’re a patient or someone interested in learning more, this guide offers insights and tools to navigate this crucial aspect of prostate cancer management. We begin with a detailed exploration of the TNM System, an internationally recognized method maintained by the Union for International Cancer Control (UICC)

To enhance your understanding, we’ve developed a Quiz that allows you to input clinical data to get a hypothetical idea of the TNM staging of your condition. It’s a practical way to see how different factors contribute to the staging process. We’ve created dedicated pages for each of the four stages complete with visual representations and textual explanations. 

Let’s start this educational journey together, towards greater understanding and awareness of prostate cancer staging.

Understanding the TNM System for Prostate Cancer

The TNM Classification of Malignant Tumours, maintained by the Union for International Cancer Control (UICC), is a globally recognized standard for classifying the extent of cancer spread. The TNM system records the primary and regional nodal extent of the tumor and the absence or presence of metastases. It’s an anatomically based system used for over 70 years and is crucial for treatment planning, prognosis, and cancer control activities (UICC).

AJCC TNM Staging System: The most recent update to the American Joint Committee on Cancer (AJCC) TNM staging system for prostate cancer was in 2018. This system is based on the extent of the primary tumor (T category), lymph node involvement (N category), metastases (M category), PSA level at diagnosis, and the Grade Group (based on the Gleason score) determined from prostate biopsy or surgery results (American Cancer Society).

The AJCC has transitioned from publishing Cancer Staging Manuals to a Cancer Staging System, moving from Editions to Versions. The most recent is Version 9, but all disease sites in the 8th Edition Cancer Staging Manual remain current until replaced with Version 9.

AJCC TNM Staging System categorizes the extent of prostate cancer based on:

  • T Category: Extent of the primary tumor
  • N Category: Spread to nearby lymph nodes
  • M Category: Metastasis to other parts of the body
  • PSA level at diagnosis
  • Grade Group (based on Gleason score)

Stages in the TNM System: The stages range from I to IV, with some stages further divided (e.g., IIA, IIB, etc.). The T category includes the clinical T category (cT), based on physical exams, prostate biopsy, and imaging tests, and the pathologic T category (pT), determined after prostate removal and lab examination. Each stage reflects how much the cancer has spread, with higher numbers indicating more advanced cancer.

Prostate cancer stagesStage1Stage2Stage3Stage4

Specifics of Each Stage:

  • Stage I: Includes cT1, N0, M0, PSA < 10, Grade Group 1.
  • Stage II: Subdivided into IIA (cT1, cT2a, or pT2, N0, M0, PSA ≥ 10 but < 20, Grade Group 1) and IIB (T1 or T2, N0, M0, PSA < 20, Grade Group 2), among others.
  • Stage III: Includes IIIA (T1 or T2, N0, M0, PSA ≥ 20, Grade Group 1-4) and IB (T3, T4, N0, M0, any PSA, Grade Group 1-4).
  • Stage IV: Divided into IVA (Any T, N1, M0, any PSA, any Grade Group) and IVB (Any T, any N, M1, any PSA, any Grade Group).

All PSA levels in the TNM system represent both ng/mL and mcg/L. The system is based on the clinical estimate of disease extent (cT) and the pathologic examination of the prostate (pT).

Welcome to your Quiz on TNM Staging

Understanding the Gleason Score System for Prostate Cancer

The Gleason grading system, developed in the 1960s by Dr. Donald Gleason, is used to grade prostate cancer cells on a scale of 1 to 5. This grading reflects how much the cancer cells have mutated from normal cells. Grade 1 cells are similar to normal prostate tissue, while cells closer to Grade 5 are considered high-grade and have significantly mutated​​.

Gleason Grades Infographic| Healthy Prostate   

The Gleason Score is derived by adding the two most common grades found in a biopsy sample. For instance, if the most common grade is 3 and the second most common is 4, the Gleason Score is 7. Currently, Gleason Scores range from 6 (the lowest grade cancer) to 10 (high-grade cancer)​​​​.

Gleason Score Categories: Gleason scores are categorized into three groups:

A lower Gleason grade suggests that the cancer is slower-growing and less aggressive. However, even a small amount of Gleason grade 5 cells in a biopsy can indicate a higher risk of recurrence​​. Gleason scores are crucial for predicting how quickly prostate cancer might grow and for guiding treatment options. They are just one of several tools used to set a prognosis and plan treatment​​.

Grade Group System: In 2014, the International Society of Urological Pathology introduced the Grade Group system, which complements the Gleason Score. This system simplifies the grading into five groups:

  • Grade Group 1: Gleason score 6 or lower (low-grade cancer).
  • Grade Group 2: Gleason score 3 + 4 = 7 (medium-grade cancer).
  • Grade Group 3: Gleason score 4 + 3 = 7 (medium-grade cancer).
  • Grade Group 4: Gleason score 8 (high-grade cancer).
  • Grade Group 5: Gleason scores 9 to 10 (high-grade cancer).

This 5-tiered Grade Group system better reflects the biological behavior of prostate cancer and is instrumental in guiding clinical care​​​​.

The Gleason Score remains a cornerstone in the grading of prostate cancer, with recent developments like the Grade Group system enhancing its clinical utility. Understanding these grading systems is vital for accurately predicting disease progression and determining the most appropriate treatment strategies. Having explored the Grade Group System, a crucial element in prostate cancer assessment, we now turn our attention to the NCCN Clinical Staging. This staging plays a pivotal role in determining the most effective treatment strategy. It takes into consideration not only the Gleason Score and PSA levels but also the extent of the tumor, lymph node involvement, and metastasis, which are all captured in the TNM system.

Introduction to NCCN Clinical Staging for Prostate Cancer

NCCN (National Comprehensive Cancer Network) Clinical Staging Guidelines are pivotal in shaping the approach to diagnosing and treating prostate cancer at various stages. The NCCN Guidelines for Prostate Cancer provide a framework for the workup of patients, risk stratification, and management of localized, recurrent, and advanced disease. This includes the management of metastatic castration-sensitive prostate cancer, nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC. This staging system is dynamic and aligns with the latest advancements in cancer care, ensuring that patients receive the most current and effective treatment options. The NCCN Guidelines offer specific recommendations for each stage of prostate cancer, helping to tailor treatment plans to individual patient needs. To understand how these guidelines apply to each stage of prostate cancer as defined by the TNM system, refer to the following pages:

TNM Stage I (Early Stage)Visit our Stage I page for insights into the NCCN recommendations for very-low-risk and low-risk prostate cancer, focusing on active surveillance and early treatment strategies.
TNM Stage II (Localized Cancer)On our Stage II page, we delve into the options for localized prostate cancer, including radiation therapy and surgery, catering to patients with intermediate-risk profiles.
TNM Stage III (Regionally Advanced Cancer)Our Stage III page covers the NCCN’s approach to treating regionally advanced prostate cancer, highlighting treatment combinations and the importance of considering the extent of cancer spread.
TNM Stage IV (Metastatic Cancer)The Stage IV page provides a comprehensive look at the management strategies for metastatic prostate cancer, discussing advanced therapies like hormonal treatments, chemotherapy, and emerging targeted therapies.

The NCCN Clinical Staging system, combined with the TNM classification and Gleason Grade Groups, forms the cornerstone of prostate cancer management. By visiting the linked pages, you can gain a deeper understanding of how these guidelines are applied in practice, ensuring a well-rounded perspective on prostate cancer treatment at each stage.


The information provided in “Mastering Prostate Cancer Staging: Your Interactive Guide to Understanding & Navigating the Grading Systems” is intended for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment options. The content, including any guidelines and insights shared here, may not encompass all possible scenarios and should not be interpreted as definitive medical advice. We do not endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned in this guide.


As we conclude “Mastering Prostate Cancer Staging: Your Interactive Guide,” we hope that the journey through the intricacies of the TNM System, the insights into the Gleason Score, and the overview of the NCCN Clinical Staging have provided you with a deeper understanding of prostate cancer management. By understanding the stages of prostate cancer, its grading, and the various treatment options, you are better equipped to make informed decisions and engage in meaningful conversations with healthcare professionals.

Call to Action

If you haven’t already, we encourage you to take the Interactive TNM Staging Quiz. It’s a unique opportunity to apply what you’ve learned and get a personalized insight into prostate cancer staging. Your feedback is invaluable. Please share your thoughts, experiences, or any questions you have in the comments section below. Your input is a source of support and information for others. Help us raise awareness about prostate cancer. Share this guide with friends, family, or anyone who may benefit from this information. Together, we can make a difference in the lives of those affected by prostate cancer.

29 thoughts on “Mastering Prostate Cancer Staging: Your Interactive Guide to Understanding & Navigating the Grading Systems”

  1. Hey Max, 

    Your article on prostate cancer staging is well-written and informative, and provides insights from both the physician and patient perspectives. Excellent job as well of presenting the information in a way that is easy to understand for patients and clinicians alike.

    Cancer has been called the Emperor of all Maladies. The more we understand it through research and information like this, the closer we get to dethroning it.

    1. Hi Ben,
      Thank you for your kind words about my article on prostate cancer staging. I’m pleased to hear that you found it both informative and accessible. Your reference to cancer as the ‘Emperor of all Maladies’ is spot on. It underscores the crucial role of education and research in our ongoing battle against this complex disease. By empowering patients and clinicians with knowledge, we indeed move closer to better management and, hopefully, the eventual defeat of cancer. If there are any specific topics or questions you would like to see addressed in future articles, please feel free to share.
      Warm regards,

  2. Hey Max! Your guide on prostate cancer staging is a crucial for everyone and especially those of us who are not quite familiar with this topic. The breakdown of the TNM system and the AJCC TNM Staging System is super helpful, especially for someone like me who’s new to all these terms. Can you share a bit about how you first got interested in making these complex medical concepts so accessible? Also, kudos on the Gleason Score breakdown—those visuals make it so much easier to grasp. Do you have any advice for someone supporting a loved one going through prostate cancer? Your insights would mean a lot. Thanks a bunch for making this knowledge less intimidating! 

    1. Hi Stephanie,

      Thank you so much for your feedback on my guide to prostate cancer staging. I’m glad to hear that the breakdowns of the TNM system and the Gleason Score were particularly helpful for you. My interest in demystifying complex medical topics grew from a desire to bridge the gap between medical jargon and patient understanding. It’s crucial for patients and their loved ones to have clear, comprehensible information to make informed decisions.
      Regarding supporting someone with prostate cancer, my top advice is to be present and listen. Each person’s experience is unique, so understanding their specific fears, concerns, and needs is key. Encourage open communication and explore resources together. Support groups can be invaluable, offering both practical advice and emotional support.
      Again, thank you for your kind words, and if there’s more you’d like to know, don’t hesitate to ask.

      Best wishes,

  3. Hey Max! Your guide on prostate cancer staging is incredibly informative, breaking down complex concepts into an easily digestible format. I appreciate the clarity on the TNM system and the Gleason Score, making it accessible for patients and those keen to learn. How frequently should individuals consider reassessing their TNM staging, especially if they’re on an active surveillance plan?

    1. Hi Stratos,

      Thank you for your positive feedback on my guide to prostate cancer staging. Regarding your question about the frequency of reassessing TNM staging for those on an active surveillance plan, it generally depends on several factors, including initial staging, PSA levels, and overall health. Typically, reassessment should be done every 6 to 12 months, but it’s important to follow the recommendations of your doctor. Regular monitoring through PSA tests, digital rectal exams, and possibly repeat biopsies is key to ensuring any changes in the cancer’s status are detected promptly.

      Best regards,

  4. While your post comprehensively covers the TNM system and the Gleason Score, it doesn’t touch upon how patient age and overall health influence treatment decisions in the context of these staging systems. How do factors like a patient’s age and comorbidities play a role in determining the most suitable treatment approach for prostate cancer?

    1. Hi Sonia,

      Thank you for your insightful comment. The primary aim of the post was to provide a clear and comprehensive understanding of the prostate cancer staging system. You raise an important point about how patient age and overall health influence treatment decisions. These factors indeed play a crucial role in determining the most suitable treatment approach. For a more detailed exploration of how these factors interplay with different stages of prostate cancer, I encourage you to take the quiz included in the post. It is designed to offer more personalized information about treatment decisions matching every stage.

      Best regards,

  5. Mastering Prostate Cancer Staging should be something every man reads. More and more men are experiencing this type of cancer than ever before.

    This article explains the stages in simple easy to understand terms. You don’t need to be a college graduate to be able to learn from reading this article.

    This is a must-read for every man. 


    1. Hi Jeff,

      Thank you so much for your encouraging words. It’s heartening to hear that the article was clear and easy to understand. You’re absolutely right about the increasing prevalence of prostate cancer, and that’s exactly why I felt it was essential to create this guide. My goal is to make crucial health information accessible to everyone, regardless of their background. I’m glad you see it as a valuable resource for all men. If there’s any other aspect of prostate cancer or its management you’re curious about, feel free to ask.

      Best regards,

  6. This is a very detailed and helpful guide of the different stages of prostate cancer. Anybody that is diagnosed with cancer, finds it frightening news, and this guide demystifies many of the scary terminology.

    I was not familiar with the TNM system and was wondering what TNM stands for. So do I understand it correctly that T would refer to the extent of the primary tumor, N would refer to whether it has spread to nearby lymph nodes, and M is metastasis to other parts of the body? Would the TNM system also be used for other types of cancer, not just cancer of the prostate? Thank you.

    1. Hi LineCowley,

      Thank you for your kind words about the “Mastering Prostate Cancer Staging” guide. I’m glad to hear it’s been helpful in clarifying some of the complex terminology associated with prostate cancer.

      You’re absolutely right in your understanding of the TNM system. TNM stands for Tumor, Nodes, and Metastasis:

      T (Tumor): Describes the size and extent of the primary tumor. In the context of prostate cancer, T stages range from T1 (tumor not palpable or visible by imaging) to T4 (tumor has spread to nearby organs).

      N (Nodes): Indicates whether the cancer has spread to nearby lymph nodes. N0 means cancer hasn’t spread to any lymph nodes, while N1 indicates it has.

      M (Metastasis): Refers to whether the cancer has spread to other parts of the body. M0 denotes no distant spread, and M1 indicates that metastases are present.

      It’s important to note that the TNM staging system is not exclusive to prostate cancer. It is a universally applied staging system used for most types of cancer, offering a common language for doctors worldwide to describe the extent of cancer spread. This system helps in determining the most effective treatment approach and understanding prognosis.

      If you have any more questions or need further clarification, feel free to ask!

      Thank you for engaging with the guide and for your insightful questions.

      Best regards,

  7. I found this article very informative and helpful in explaining the TNM System for prostate cancer and the Gleason Score System. The TNM System describes the size and extent of the tumor, the involvement of the lymph nodes, and the presence of metastasis. 

    1. The Gleason Score System grades the cancer cells based on how abnormal they look under a microscope, and how likely they are to grow and spread quickly 

    2. Both systems are important in determining the prognosis and treatment options for prostate cancer patients.

    I have a question for anyone who has experience with these systems. How accurate and reliable are they in predicting the outcome of prostate cancer? I have a friend who was diagnosed with prostate cancer last year, and he had a low TNM stage (T2N0M0) and a low Gleason score (6). He opted for active surveillance, which means he did not receive any immediate treatment, but he had regular tests and check-ups to monitor his cancer. He seemed to be doing well, until his last PSA test showed a sudden increase in his level. He had another biopsy, and his Gleason score had changed to 9, which means he had a high-grade and aggressive cancer. 

    3. He was shocked and scared, and he decided to have surgery to remove his prostate. He is now recovering from the surgery, but he is worried about the possible side effects and complications, such as incontinence and impotence.

    I am very concerned for him, and I wonder if there was anything he could have done differently to prevent his cancer from getting worse. Did the TNM System and the Gleason Score System fail to detect his true cancer stage and grade? Or did his cancer change and progress rapidly in a short time? How common is this situation, and what are the factors that influence it? I would appreciate any insights or advice from anyone who has gone through something similar, or who knows more about these systems. Thank you for reading my comment.

    1. Hi Akimat Sloutions,
      Your concern for your friend and the questions you raise about the TNM and Gleason scoring systems are both understandable and important. Prostate cancer staging and grading are complex and evolving areas in oncology and we have to aproach them with nuanced undertanding.
      TNM System’s Accuracy: The TNM (Tumor, Nodes, Metastasis) system is used worldwide for cancer staging, including prostate cancer. It provides a standardized way to describe the extent of cancer spread. However, it’s essential to recognize that while the TNM system is valuable for treatment planning and prognostication, it is not able to always capture the full complexity of individual cancer cases. In prostate cancer, for example, the number of positive lymph nodes (N stage) and the extent of the primary tumor (T stage) provide crucial information, but they may not fully account for the biological behavior of the tumor​​.
      The Gleason score, on the other hand, grades prostate cancer based on how abnormal the cancer cells look under the microscope. While the Gleason score is a valuable tool in assessing prostate cancer’s aggressiveness and guiding treatment decisions, it’s just one part of a larger picture. It is important to consider other diagnostic results and biopsy information alongside the Gleason score when predicting the behavior of prostate cancer​​.
      Regarding your friend’s situation, it is indeed possible for prostate cancer to change and progress, even if initially diagnosed as low-grade. Prostate cancer is known for its heterogeneity, meaning that it can behave differently in different patients. A sudden increase in PSA levels and a change in the Gleason score, as seen in your friend’s case, can indicate a shift towards a more aggressive form of cancer. This underscores the importance of regular monitoring and reassessment in cases where active surveillance is chosen.
      It’s challenging to say definitively if anything could have been done differently in your friend’s case without knowing all the specific details. The decision for active surveillance in low-grade prostate cancer (like a T2N0M0 stage and Gleason score of 6) is generally based on current best practices and guidelines, aiming to balance the risks and benefits of immediate treatment versus observation. Unfortunately, cancer can sometimes progress despite these measures. Rapid progression like your friend experienced is not the most common scenario but is a known possibility in prostate cancer management. The factors influencing such progression are complex and can include genetic, biological, and possibly environmental factors.
      I hope your friend recovers well from his surgery and manages any side effects effectively. His experience underscores the unpredictable nature of cancer and the importance of personalized care in oncology.
      Please do not hesitate to reach out for more information or support.

      Best Regards,

  8. While I do not have a prostate, my husband does and has been having some issues in that area as well. 

    While we hope it is not the prostate, we are taking the necessary precautions with doctor visits when he is home from his runs, he is an OTRT, which makes getting the diagnosis in a timely manner a tad inconvenient. 

    Locating articles like this one, Mastering Prostate Cancer Staging: Your Interactive Guide to Understanding & Navigating the Grading Systems, has been most enlightening. 

    Understanding these different scoring systems and what they mean before you start getting diagnosed can be very beneficial, as it takes the guessing game out of what the doctor just said. I will have to read through them again to gain a full understanding, I have the page bookmarked now so I can find it easier later.

    I read and learn all the things, and then I explain things to my husband when the doctor leaves the room, and he thinks I am a genius, I won’t tell him my little secret if you don’t.

    Thank you for this article, I have found it quite helpful and educational. I look forward to bugging my husband with the quiz when he gets home.


    1. Hi Stacie,
      Thank you for sharing your thoughts on the “Mastering Prostate Cancer Staging” guide. It’s heartening to hear that the information has been useful to you and your husband, especially given the challenges of managing health concerns with an OTRT schedule.
      Your proactive approach to understanding prostate cancer staging and grading systems is commendable. By familiarizing yourself with these systems, you’re not only preparing to have more informed discussions with your husband’s doctors, but you’re also providing invaluable support to your husband during a potentially stressful time.
      It’s great that you’ve bookmarked the page for easy reference. Remember, these systems can be intricate, and it’s perfectly normal to need a few read-throughs to fully grasp the details.
      Your role in explaining things to your husband and making sure he’s kept in the loop is incredibly important. It’s clear you’re doing a fantastic job! If you have any further questions or need more resources, feel free to reach out.
      Wishing you and your husband the best in navigating this journey together. Keep up the great work!

      Best Regards,

  9. What an informative article! This topic is so very important and a necessary read. You really broke everything down and explained it incredibly well. I had no idea what the TNM system was nor did I know anything about the Gleason score or mutated cell growth. Thank you for the valuable information you shared! 

    1. Hi Randi,
      Thank you so much for your kind words about the “Mastering Prostate Cancer Staging” article. I’m thrilled to know that it provided you with valuable information and helped demystify the TNM system and the Gleason score. Understanding these concepts can be quite challenging, especially for those who are encountering them for the first time.
      If you have any further questions or if there are other aspects of prostate cancer or its staging that you’re curious about, please don’t hesitate to reach out. This is a topic with many layers, and there’s always more to learn and understand.
      Again, thank you for taking the time to read and engage with the article. Your feedback is greatly appreciated, and it’s heartening to know that the guide is making a positive impact.

      Best Regards,

  10. Subject of prostate cancer is very close to my heart because I suffered from it. About 10 years ago I was diagnosed with Prostate cancer at the age of 60. It was a shock to me. MY PSA level was very high. Immediately I went into an action mode. Upon meeting with the specialist I was given 2 choices- Prostate surgery or Chemotherapy. Both had it’s pros and cons. I decided to go with the surgery. It was successful and my prostate cancer never returned. I did have some side affects but nothing big. Prostate cancer is very common amongst older men. 

    The post is very educational even though some medical terms are beyond my comprehension.

    Greatly appreciated.

    1. Hi Gary,
      Thank you for sharing your personal experience with prostate cancer. Hearing from someone who has been through the diagnosis and treatment process adds a deeply valuable perspective to the discussion. I’m glad to hear that your surgery was successful and that you’ve been cancer-free since then.
      Your story is a testament to the importance of being proactive about health, especially when it comes to conditions like prostate cancer, which, as you mentioned, is indeed common among older men. Your decision-making process and the choices you faced are reflective of the complex and often difficult decisions many men with prostate cancer confront.
      Thank you once again for your comment and for highlighting the significance of this topic. Wishing you continued good health and well-being.

      Best Regards,

  11. Hi,

    Reading this article has really opened my eyes to the severity or understanding and what prostate cancer is, I’ve always heard about the stages but seeing the images used to show the progression it makes within shows the importance of getting checked. Having family members affected by prostate cancer this article has helped me understand what it is and how it is detected.

    Insightful article, well done 

    1. Hi Shannon,
      Thank you so much for your comment! I’m pleased to hear that the article on prostate cancer staging resonated with you. Understanding the progression and detection of prostate cancer is indeed crucial, especially when it touches our loved ones. I’m glad the article provided you with valuable insights. If you have any further questions or need more information about prostate cancer or its management, feel free to ask.
      Your engagement and feedback are immensely appreciated!

      Best wishes,

  12. Hello Max! I have had the pleasure of reviewing your post on Mastering Prostate Cancer Staging.  I have also sifted through the comments made and I agree that your content goes a long way toward demystifying a topic that, sadly, affects many.  I appreciate and admire your motivation to bridge the gap between medical jargon and and patient understanding.  As a lawyer for over 38 years, your motivation in this regard resonates with me.  I think that, for too long, professionals kept their clients and patients, the most important players in the mix, out of the loop.  For me, I did my best, in both verbal and written communication with clients, to avoid the use of legalese and frame my dialogue with them in language they could easily  understand.  I have always felt that my best client was an educated client.  I’m confidently guessing that you would agree.

    Thank you for sharing this valuable content.  My audience currently is the 65 and over crowd so, for me, understanding this material is going to be very helpful.

    1. Hello Grant,
      Thank you for taking the time to share your thoughts and experiences! It’s especially meaningful coming from someone with your extensive background in law and your commitment to clear communication. Your approach to legal communication, focusing on clarity and education, is a philosophy, I embrace in my writing as well.
      I’m also in my 70th decade, so topics like prostate cancer hold personal significance for me and many in our age group. Ensuring that our peers have access to understandable and relevant health information is a mission close to my heart.
      I’m pleased to know that this article will be a resource for you and your audience. If you have any specific topics or questions in mind that you think would benefit your audience, please feel free to suggest them. I’m always looking for ways to tailor content to my readers’ needs.
      Thank you again for your kind words and for the impactful work you’ve done in your field. Let’s continue to make complex information accessible and useful to those who need it most.

      Warm regards,

  13. Hi Max, what a fantastic article. Not only is it well written, it’s very informative. I’m sure many people will be helped by this article. I like that you included the disclaimer so as to not have people confuse you with the medical profession. However, I fully believe that we are all the CEO of our own health. The medical profession know more than most of us about a lot of things, but they don’t know everything. I never had prostate cancer but I’ve had head and neck cancer which I have beaten. I’m dealing with another kind of cancer now. I hope prostate cancer is not in my future. I’m also a believer in prevention. I do all I can to prevent myelf from getting anything, including cancer. Meanwhile, I like to gather as much information as possible. You never know if and when you might need it.


    1. Hi Bob,
      Thank you so much for your kind words about my article on “Mastering Prostate Cancer Staging.” Your viewpoint as someone who has battled cancer is incredibly valuable, and your proactive approach to health is truly inspiring.
      I completely agree with you that we are the CEOs of our own health. It’s so important to be informed and take an active role in our healthcare decisions. I’m sorry to hear that you’re facing another battle with cancer, but your strength and positive attitude are remarkable. I hope that prostate cancer never becomes a part of your journey, but it’s great that you’re staying informed just in case.
      If you ever have any questions or need more information, feel free to reach out.
      Best wishes and good health,

  14. I found an informative article on a part of male health that is often overlooked by many men.

     I am grateful for the author’s effort in writing this article, and I will use it as a reference in the future. I liked how you click on the images and see in more detail what was going on. However, I am concerned about the low rate of male screening.

     I wonder if there are any ideas to encourage more men to screen themselves. Despite this, I believe this article is a great resource and I will share it with my friends and colleagues.

    1. Hi A,
      Thank you for your kind words and feedback. It’s encouraging to hear that you found the article useful. Regarding your concern about the low rate of male screening, raising awareness through education and making screening more accessible are key strategies. Initiatives like community health events, engaging social media campaigns, and simplifying the screening process can help. Encouraging open conversations among friends, family, and on platforms like this also plays a crucial role in breaking down stigmas associated with screening.
      I’m glad you’ll be sharing the article.

      Best regards,

  15. I thankfully have no family members or friends who are in need of treatment for prostate cancer, but I still wanted to learn more. This was a really good read for that purpose. 

    I can’t say that I’m all that knowledgable now, as my memory is not quite that good, but I do feel more informed and relaxed knowing that I have some knowledge if it were ever needed.

    Thank you for sharing this important information, I hope that it helps many people.

Leave a Reply

Your email address will not be published. Required fields are marked *